Some Nrf2 inhibitors, such as brusatol or halofuginone have been shown to sensitize cancer cells to chemo- and radiotherapy; however, these drugs require a suitable delivery system directly to the cancerous tissue in order to do no harm to healthy organs and tissues. This evidence concerns the gene NFE2L2 and cancer.